Late and chronic antibody-mediated rejection: Main barrier to long term graft survival

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Sun, Qiquan ^a   Yang, Yang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BORTEZOMIB; COMPLEMENT COMPONENT C4D; ECULIZUMAB; HLA ANTIBODY; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID; RITUXIMAB; STEROID; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; CAPILLARITIS; CAPILLARY BASEMENT MEMBRANE; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC ANTIBODY MEDIATED REJECTION; DRUG SAFETY; GLOMERULITIS; GLOMERULOPATHY; GLOMERULUS BASEMENT MEMBRANE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOADSORPTION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; LATE ANTIBODY MEDIATED REJECTION; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; LUNG TOXICITY; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; REVIEW; SINGLE DRUG DOSE; SPLENECTOMY; STEROID THERAPY; T CELL MEDIATED REJECTION; TREATMENT DURATION; TREATMENT RESPONSE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; IMMUNOLOGY; ORGAN TRANSPLANTATION;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION;

EID: 84886702798     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/859761     Document Type: Review

References (71)

1. Wolfe R. A., Ashby V. B., Milford E. L., Ojo A. O., Ettenger R. E., Agodoa L. Y. C., Held P. J., Port F. K., Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. New England Journal of Medicine 1999 341 23 1725 1730 2-s2.0-0033518231 10.1056/NEJM199912023412303
2. Li C., Yang C. W., The pathogenesis and treatment of chronic allograft nephropathy. Nature Reviews Nephrology 2009 5 9 513 519 2-s2.0-70349309684 10.1038/nrneph.2009.113
3. Nankivell B. J., Kuypers D. R., Diagnosis and prevention of chronic kidney allograft loss. The Lancet 2011 378 9800 1428 1437 2-s2.0-80054712257 10.1016/S0140-6736(11)60699-5
4. Colvin R. B., Smith R. N., Antibody-mediated organ-allograft rejection. Nature Reviews Immunology 2005 5 10 807 817 2-s2.0-25844480988 10.1038/nri1702 (Pubitemid 41400854)
5. Takemoto S. K., Zeevi A., Feng S., Colvin R. B., Jordan S., Kobeshigawa J., Kupiec-Weglinski J., Matas A., Montgomery R. A., Nickerson P., Platt J. L., Rabb H., Thistlethwaite R., Tyan D., Delmonico F. L., National conference to assess antibody-mediated rejection in solid organ transplantation. American Journal of Transplantation 2004 4 7 1033 1041 2-s2.0-3042743987 10.1111/j.1600-6143.2004.00500.x (Pubitemid 38868592)
6. Einecke G., Sis B., Reeve J., Mengel M., Campbell P. M., Hidalgo L. G., Kaplan B., Halloran P. F., Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. American Journal of Transplantation 2009 9 11 2520 2531 2-s2.0-70350131760 10.1111/j.1600-6143.2009. 02799.x
7. Sellarés J., De Freitas D. G., Mengel M., Reeve J., Einecke G., Sis B., Hidalgo L. G., Famulski K., Matas A., Halloran P. F., Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. American Journal of Transplantation 2012 12 2 388 399 2-s2.0-84856411838 10.1111/j.1600-6143.2011.03840.x
8. Colvin R. B., Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. Journal of the American Society of Nephrology 2007 18 4 1046 1056 2-s2.0-34047236016 10.1681/ASN.2007010073 (Pubitemid 46536891)
9. Racusen L. C., Colvin R. B., Solez K., Mihatsch M. J., Halloran P. F., Campbell P. M., Cecka M. J., Cosyns J., Demetris A. J., Fishbein M. C., Fogo A., Furness P., Gibson I. W., Glotz D., Hayry P., Hunsickern L., Kashgarian M., Kerman R., Magil A. J., Montgomery R., Morozumi K., Nickeleit V., Randhawa P., Regele H., Seron D., Seshan S., Sund S., Trpkov K., Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. American Journal of Transplantation 2003 3 6 708 714 2-s2.0-10744233377 10.1034/j.1600-6143.2003.00072.x (Pubitemid 36745243)
10. Sis B., Jhangri G. S., Bunnag S., Allanach K., Kaplan B., Halloran P. F., Endothelial gene expression in kidney transplants with alloantibody indicates Antibody-mediated damage despite lack of C4d staining. American Journal of Transplantation 2009 9 10 2312 2323 2-s2.0-70349196778 10.1111/j.1600-6143.2009. 02761.x
11. Sis B., Halloran P. F., Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Current Opinion in Organ Transplantation 2010 15 1 42 48 2-s2.0-75749105115 10.1097/MOT. 0b013e3283352a50
12. Cosio F. G., Gloor J. M., Sethi S., Stegall M. D., Transplant glomerulopathy. American Journal of Transplantation 2008 8 3 492 496 2-s2.0-39649115166 10.1111/j.1600-6143.2007.02104.x (Pubitemid 351287536)
13. Sun Q., Huang X., Jiang S., Zeng C., Liu Z., Picking transplant glomerulopathy out of the CAN: evidence from a clinico-pathological evaluation. BMC Nephrology 2012 13, article 128
14. Haas M., Pathology of C4d-negative antibody-mediated rejection in renal allografts. Current Opinion in Organ Transplantation 2013 18 319 326
15. Halloran P. F., Sellares J., Microcirculation lesions alone are not reliable for identifying antibody-mediated rejection. American Journal of Transplantation 2013 13 1931 1932
16. Sun Q., Cheng D., Zhang M., He Q., Chen Z., Liu Z., Predominance of intraglomerular T-bet or GATA3 may determine mechanism of transplant rejection. Journal of the American Society of Nephrology 2011 22 2 246 252 2-s2.0-79551666049 10.1681/ASN.2010050471
17. Sun Q., Zhang M., Xie K., Li X., Zeng C., Zhou M., Liu Z., Endothelial injury in transplant glomerulopathy is correlated with transcription factor T-bet expression. Kidney International 2012 82 321 329 2-s2.0-84859738847 10.1038/ki.2012.112
18. Solez K., Colvin R. B., Racusen L. C., Haas M., Sis B., Mengel M., Halloran P. F., Baldwin W., Banfi G., Collins A. B., Cosio F., David D. S. R., Drachenberg C., Einecke G., Fogo A. B., Gibson I. W., Glotz D., Iskandar S. S., Kraus E., Lerut E., Mannon R. B., Mihatsch M., Nankivell B. J., Nickeleit V., Papadimitriou J. C., Randhawa P., Regele H., Renaudin K., Roberts I., Seron D., Smith R. N., Valente M., Banff 07 classification of renal allograft pathology: updates and future directions. American Journal of Transplantation 2008 8 4 753 760 2-s2.0-40449101372 10.1111/j.1600-6143.2008.02159.x (Pubitemid 351347767)
19. Sun Q., Liu Z.-H., Ji S., Chen J., Tang Z., Zeng C., Zheng C., Li L.-S., Late and early C4d-positive acute rejection: different clinico-histopathological subentities in renal transplantation. Kidney International 2006 70 2 377 383 2-s2.0-33746168208 10.1038/sj.ki.5001552 (Pubitemid 44086589)
20. Dorje C., Midtvedt K., Holdaas H., Early versus late acute antibody-mediated rejection in renal transplant recipients. Transplantation 2013
21. Walsh R. C., Brailey P., Girnita A., Alloway R. R., Shields A. R., Wall G. E., Sadaka B. H., Cardi M., Tevar A., Govil A., Mogilishetty G., Roy-Chaudhury P., Woodle E. S., Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 2011 91 11 1218 1226 2-s2.0-79958245423 10.1097/TP. 0b013e318218e901
22. Pascual J., Samaniego M. D., Torrealba J. R., Odorico J. S., Djamali A., Becker Y. T., Voss B., Leverson G. E., Knechtle S. J., Sollinger H. W., Pirsch J. D., Antibody-mediated rejection of the kidney after simultaneous pancreas-kidney transplantation. Journal of the American Society of Nephrology 2008 19 4 812 824 2-s2.0-44349171831 10.1681/ASN.2007070736
23. Chapman J. R., O'Connell P. J., Nankivell B. J., Chronic renal allograft dysfunction. Journal of the American Society of Nephrology 2005 16 10 3015 3026 2-s2.0-31644434259 10.1681/ASN.2005050463 (Pubitemid 44743499)
24. Solez K., Colvin R. B., Racusen L. C., Sis B., Halloran P. F., Birk P. E., Campbell P. M., Cascalho M., Collins A. B., Demetris A. J., Drachenberg C. B., Gibson I. W., Grimm P. C., Haas M., Lerut E., Liapis H., Mannon R. B., Marcus P. B., Mengel M., Mihatsch M. J., Nankivell B. J., Nickeleit V., Papadimitriou J. C., Platt J. L., Randhawa P., Roberts I., Salinas-Madriga L., Salomon D. R., Seron D., Sheaff M., Weening J. J., Banff 05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN). American Journal of Transplantation 2007 7 3 518 526 2-s2.0-33847761900 10.1111/j.1600-6143.2006.01688.x (Pubitemid 46376465)
25. Lee P.-C., Terasaki P. I., Takemoto S. K., Lee P.-H., Hung C.-J., Chen Y.-L., Tsai A., Lei H.-Y., All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002 74 8 1192 1194 2-s2.0-0037184308 (Pubitemid 35216119)
26. Everly M. J., Rebellato L. M., Haisch C. E., Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013 95 410 417
27. Campos É. F., Tedesco-Silva H., Machado P. G., Franco M., Medina-Pestana J. O., Gerbase-DeLima M., Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. American Journal of Transplantation 2006 6 10 2316 2320 2-s2.0-33748504807 10.1111/j.1600-6143. 2006.01503.x (Pubitemid 44359416)
28. Wiebe C., Gibson I. W., Blydt-Hansen T. D., Karpinski M., Ho J., Storsley L. J., Goldberg A., Birk P. E., Rush D. N., Nickerson P. W., Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. American Journal of Transplantation 2012 12 5 1157 1167 2-s2.0-84860473178 10.1111/j.1600-6143.2012.04013.x
29. Nickeleit V., Mihatsch M. J., Kidney transplants, antibodies and rejection: is C4d a magic marker? Nephrology Dialysis Transplantation 2003 18 11 2232 2239 2-s2.0-0242351702 10.1093/ndt/gfg304 (Pubitemid 37336808)
30. Singh N., Sun Q., Nadasdy T., The pathogenesis of acute allograft dysfunction in desensitized renal transplant recipients. Clinical Transplantation 2012 26 E402 E411
31. Lefaucheur C., Loupy A., Vernerey D., Antibody-mediated vascular rejection of kidney allografts: a population-based study. The Lancet 2013 381 313 319
32. Bradley J. A., Baldwin W. M., Bingaman A., Ellenrieder C., Gebel H. M., Glotz D., Kirk A. D., Antibody-mediated rejection-an ounce of prevention is worth a pound of cure. American Journal of Transplantation 2011 11 6 1131 1139 2-s2.0-79958803569 10.1111/j.1600-6143.2011.03581.x
33. Morath C., Opelz G., Zeier M., Susal C., Prevention of antibody-mediated kidney transplant rejection. Transplant International 2012 25 633 645
34. Theruvath T. P., Saidman S. L., Mauiyyedi S., Delmonico F. L., Williams W. W., Tolkoff-Rubin N., Bernard Collins A., Colvin R. B., Benedict Cosimi A., Pascual M., Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 2001 72 1 77 83 2-s2.0-17844362457 10.1097/00007890-200107150- 00016 (Pubitemid 32652509)
35. Sun Q., Liu Z.-H., Cheng Z., Chen J., Ji S., Zeng C., Li L.-S., Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetil. Kidney International 2007 71 1 24 30 2-s2.0-33845703244 10.1038/sj.ki.5001870 (Pubitemid 44967730)
36. Sun Q., Liu Z.-H., Yin G., Chen H., Chen J., Ji S., Li L.-S., Tacrolimus combined with mycophenolate mofetil can effectively reverse C4d-positive steroid-resistant acute rejection in Chinese renal allograft recipients. Nephrology Dialysis Transplantation 2006 21 2 510 517 2-s2.0-31544455528 10.1093/ndt/gfk027 (Pubitemid 43160010)
37. Pascual M., Saidman S., Tolkoff-Rubin N., Williams W. W., Mauiyyedi S., Duan J. M., Farell M. L., Colvin R. B., Delmonico F. L., Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1999 66 1460 1464 2-s2.0-0033557203
38. Böhmig G. A., Regele H., Exner M., Derhartunian V., Kletzmayr J., Säemann M. D., Hörl W. H., Druml W., Watschinger B., C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. Journal of the American Society of Nephrology 2001 12 11 2482 2489 2-s2.0-0034759065 (Pubitemid 33021127)
39. Jordan S. C., Quartel A. W., Czer L. S. C., Admon D., Chen G., Fishbein M. C., Schwieger J., Steiner R. W., Davis C., Tyan D. B., Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral reaction in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998 66 6 800 808 2-s2.0-0032572976 10.1097/00007890-199809270-00017 (Pubitemid 28460117)
40. Casadei D. H., Del C. Rial M., Opelz G., Golberg J. C., Argento J. A., Greco G., Guardia O. E., Haas E., Raimondi E. H., A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001 71 1 53 58 2-s2.0-0035863090 (Pubitemid 32105778)
41. Faguer S., Kamar N., Guilbeaud-Frugier C., Fort M., Modesto A., Mari A., Ribes D., Cointault O., Lavayssière L., Guitard J., Durand D., Rostaing L., Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007 83 9 1277 1280 2-s2.0-34248355550 10.1097/01.tp.0000261113. 30757.d1 (Pubitemid 46743692)
42. Mulley W. R., Hudson F. J., Tait B. D., Skene A. M., Dowling J. P., Kerr P. G., Kanellis J., A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation 2009 87 2 286 289 2-s2.0-59549107898 10.1097/TP.0b013e31819389cc
43. Everly M. J., Everly J. J., Susskind B., Brailey P., Arend L. J., Alloway R. R., Roy-Chaudhury P., Govil A., Mogilishetty G., Rike A. H., Cardi M., Wadih G., Tevar A., Woodle E. S., Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008 86 12 1754 1761 2-s2.0-58849136282 10.1097/TP.0b013e318190af83
44. Flechner S. M., Fatica R., Askar M., Stephany B. R., Poggio E., Koo A., Banning S., Chiesa-Vottero A., Srinivas T., The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010 90 12 1486 1492 2-s2.0-78650840827 10.1097/TP.0b013e3181fdd9b0
45. Gonzalez-Roncero F., Suner M., Bernal G., Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplantation Proceedings 2012 44 2690 2694
46. Locke J. E., Magro C. M., Singer A. L., Segev D. L., Haas M., Hillel A. T., King K. E., Kraus E., Lees L. M., Melancon J. K., Stewart Z. A., Warren D. S., Zachary A. A., Montgomery R. A., The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. American Journal of Transplantation 2009 9 1 231 235 2-s2.0-58049206825 10.1111/j.1600-6143. 2008.02451.x
47. Locke J. E., Zachary A. A., Haas M., Melancon J. K., Warren D. S., Simpkins C. E., Segev D. L., Montgomery R. A., The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. American Journal of Transplantation 2007 7 4 842 846 2-s2.0-33947591440 10.1111/j.1600-6143.2006. 01709.x (Pubitemid 46481192)
48. Kaplan B., Gangemi A., Thielke J., Oberholzer J., Sankary H., Benedetti E., Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 2007 83 1 99 100 2-s2.0-33846185513 10.1097/01.tp.0000243739.31440.2b (Pubitemid 46104982)
49. Billing H., Rieger S., Ovens J., Süsal C., Melk A., Waldherr R., Opelz G., Tönshoff B., Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 2008 86 9 1214 1221 2-s2.0-58149153156 10.1097/TP. 0b013e3181880b35
50. Fehr T., Rüsi B., Fischer A., Hopfer H., Wüthrich R. P., Gaspert A., Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009 87 12 1837 1841 2-s2.0-67649592390 10.1097/TP.0b013e3181a6bac5
51. Hong Y. A., Kim H. G., Choi S. R., Sun I. O., Park H. S., Chung B. H., Choi B. S., Park C. W., Kim Y. S., Yang C. W., Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection. Transplantation Proceedings 2012 44 1 182 184 2-s2.0-84858734493 10.1016/j.transproceed.2011.12.006
52. Smith R. N., Malik F., Goes N., Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. Transplant Immunology 2012 27 107 113
53. Perry D. K., Burns J. M., Pollinger H. S., Amiot B. P., Gloor J. M., Gores G. J., Stegall M. D., Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. American Journal of Transplantation 2009 9 1 201 209 2-s2.0-58049200722 10.1111/j.1600-6143.2008. 02461.x
54. Walsh R. C., Alloway R. R., Girnita A. L., Woodle E. S., Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney International 2012 81 1067 1074 2-s2.0-84856988249 10.1038/ki.2011.502
55. Woodle E. S., Rubin M., Proteasome inhibitor therapy for antibody mediated rejection: initial report from a multicenter collaborative. American Journal of Transplantation 2010 10 4: article 83
56. Ashton-Chess J., Mai H. L., Jovanovic V., Renaudin K., Foucher Y., Giral M., Moreau A., Dugast E., Mengel M., Racapé M., Danger R., Usal C., Smit H., Guillet M., Gwinner W., Berre L. L., Dantal J., Soulillou J.-P., Brouard S., Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection. Kidney International 2010 77 10 880 890 2-s2.0-77951879580 10.1038/ki.2010.15
57. Alachkar N., Bagnasco S. M., Montgomery R. A., Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft. Transplant International 2012 25 e93 e95
58. Stegall M. D., Diwan T., Raghavaiah S., Cornell L. D., Burns J., Dean P. G., Cosio F. G., Gandhi M. J., Kremers W., Gloor J. M., Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. American Journal of Transplantation 2011 11 11 2405 2413 2-s2.0-84555210096 10.1111/j.1600-6143.2011.03757.x
59. Stewart Z. A., Collins T. E., Schlueter A. J., Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transplantation Proceedings 2012 44 3033 3036
60. Ishida H., Omoto K., Shimizu T., Shirakawa H., Nishida H., Xiaobei L., Yamaguchi Y., Tanabe K., Usefulness of splenectomy for chronic active antibody-mediated rejection after renal transplantation. Transplant International 2008 21 6 602 604 2-s2.0-42649111647 10.1111/j.1432-2277.2008. 00653.x (Pubitemid 351600068)
61. Hubscher S. G., Antibody-mediated rejection in the liver allograft. Current Opinion in Organ Transplantation 2012 17 280 286
62. Bellamy C. O. C., Complement C4d immunohistochemistry in the assessment of liver allograft biopsy samples: applications and pitfalls. Liver Transplantation 2011 17 7 747 750 2-s2.0-79959824372 10.1002/lt.22323
63. Ali S., Ormsby A., Shah V., Segovia M. C., Kantz K. L., Skorupski S., Eisenbrey A. B., Mahan M., Huang M. A. Y., Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection. Transplant Immunology 2012 26 1 62 69 2-s2.0-82955237624 10.1016/j.trim.2011.08.005
64. Neuman U. P., Neuhaus P., C4d immunostaining in acute humoral rejection after ABO blood group-incompatible liver transplantation. Liver Transplantation 2006 12 3 356 357 2-s2.0-33645287293 10.1002/lt.20658
65. Murata K., Baldwin W. M. III, Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplantation Reviews 2009 23 3 139 150 2-s2.0-67349163732 10.1016/j.trre.2009.02.005
66. Stewart S., Winters G. L., Fishbein M. C., Tazelaar H. D., Kobashigawa J., Abrams J., Andersen C. B., Angelini A., Berry G. J., Burke M. M., Demetris A. J., Hammond E., Itescu S., Marboe C. C., McManus B., Reed E. F., Reinsmoen N. L., Rodriguez E. R., Rose A. G., Rose M., Suciu-Focia N., Zeevi A., Billingham M. E., Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. Journal of Heart and Lung Transplantation 2005 24 11 1710 1720 2-s2.0-22144434185 10.1016/j.healun.2005. 03.019 (Pubitemid 41641841)
67. Chih S., Tinckam K. J., Ross H. J., A survey of current practice for antibody-mediated rejection in heart transplantation. American Journal of Transplantation 2013 13 1069 1074
68. Hodges A. M., Lyster H., McDermott A., Rice A. J., Smith J. D., Rose M. L., Banner N. R., Late antibody-mediated rejection after heart transplantation following the development of de Novo Donor-specific human leukocyte antigen antibody. Transplantation 2012 93 6 650 656 2-s2.0-84858708333 10.1097/TP.0b013e318244f7b8
69. Hachem R., Antibody-mediated lung transplant rejection. Current Respiratory Care Reports 2012 1 157 161
70. Drachenberg C. B., Torrealba J. R., Nankivell B. J., Rangel E. B., Bajema I. M., Kim D. U., Arend L., Bracamonte E. R., Bromberg J. S., Bruijn J. A., Cantarovich D., Chapman J. R., Farris A. B., Gaber L., Goldberg J. C., Haririan A., Honsová E., Iskandar S. S., Klassen D. K., Kraus E., Lower F., Odorico J., Olson J. L., Mittalhenkle A., Munivenkatappa R., Paraskevas S., Papadimitriou J. C., Randhawa P., Reinholt F. P., Renaudin K., Revelo P., Ruiz P., Samaniego M. D., Shapiro R., Stratta R. J., Sutherland D. E. R., Troxell M. L., Voska L., Seshan S. V., Racusen L. C., Bartlett S. T., Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. American Journal of Transplantation 2011 11 9 1792 1802 2-s2.0-80052265100 10.1111/j.1600-6143.2011.03670.x
71. Dick A. A. S., Horslen S., Antibody-mediated rejection after intestinal transplantation. Current Opinion in Organ Transplantation 2012 17 250 257 2-s2.0-84859246558 10.1097/MOT.0b013e3283533847